The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Grin Therapeutics’ radiprodil for treating seizures associated with glutamate receptor, ionotropic, N-methyl D ...
The FDA has granted Breakthrough Therapy designation to radiprodil for the treatment of seizures associated with GRIN-related neurodevelopmental disorder with GoF mutations.
The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor ...
Cancer spreading to the lungs is a common and concerning development in advanced stages of the disease. More than half of people with advanced cancer in other parts of their body eventually ...